Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

Bibliographic Details

Main Authors:	Heudobler, Daniel (Author) , Luke, Florian (Author) , Hahn, Joachim (Author) , Grube, Matthias (Author) , Schlosser, Pavla (Author) , Kremers, Stephan (Author) , Sudhoff, Thomas (Author) , Westermann, Jorg (Author) , Hutter-Kronke, Marie Luise (Author) , Schlenk, Richard Friedrich (Author) , Weber, Daniela (Author) , Paschka, Peter (Author) , Zeman, Florian (Author) , Dohner, Hartmut (Author) , Herr, Wolfgang (Author) , Reichle, Albrecht (Author) , Thomas, Simone (Author)
Format:	Article (Journal) Editorial
Language:	English
Published:	April 2024
In:	Haematologica Year: 2024, Volume: 109, Issue: 4, Pages: 1274-1278
ISSN:	1592-8721
DOI:	10.3324/haematol.2023.283864
Online Access:	lizenzpflichtig lizenzpflichtig
Author Notes:	Daniel Heudobler, Florian Luke, Joachim Hahn, Matthias Grube, Pavla Schlosser, Stephan Kremers, Thomas Sudhoff, Jorg Westermann, Marie Luise Hutter-Kronke, Richard F. Schlenk, Daniela Weber, Peter Paschka, Florian Zeman, Hartmut Dohner, Wolfgang Herr, Albrecht Reichle and Simone Thomas